Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2008 Oct;65(10):1281-3.
doi: 10.1001/archneur.65.10.1281.

Biopsy support for the validity of Pittsburgh compound B positron emission tomography with a twist

William E Klunk
Editorial

Biopsy support for the validity of Pittsburgh compound B positron emission tomography with a twist

William E Klunk. Arch Neurol. 2008 Oct.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Engler H, Blomqvist G, Bergstrom M, et al. First human study with a benzothiazole amyloid-imaging agent in Alzheimer’s disease and control subjects. Neurobiol Aging. 2002;23(suppl 1):S429.
    1. Klunk WE, Lopresti BJ, Ikonomovic MD, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer’s disease brain but not in transgenic mouse brain. J Neurosci. 2005;25(46):10598–10606. - PMC - PubMed
    1. Klunk WE, Wang Y, Huang GF, et al. The binding of 2-(4’-methylaminophenyl) benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci. 2003;23(6):2086–2092. - PMC - PubMed
    1. Bacskai BJ, Hickey GA, Skoch J, et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci U S A. 2003;100(21):12462–12467. - PMC - PubMed
    1. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306–319. - PubMed

MeSH terms

Substances